[Urine free light chains kappa in multiple sclerosis].
The evaluation of free light chains kappa in urine was performed in 77 cases of multiple sclerosis, including 52 patients before and after treatment with 2 CDA and in 25 patients before and after therapy with high doses of prednisone. The high variations in the level of free kappa chains indicate a limited diagnostic value, and only for cases with very high level. We have found effect of 2 CDA therapy in chronic progressive MS group on free kappa light chain value. A significant effect of prednisone treatment was observed in early onset cases of multiple sclerosis and in cases with clinical improvement after therapy. In conclusion, the study suggests that urinary free light chains level may be considered as one of markers for monitoring of the effect of therapy on the activity of the immunological processes in multiple sclerosis.
Michałowska-Wender
G
G
Zespołu Neuroimmunologicznego Centrum Medycyny Doświadczalnej i Klinicznej PAN w Poznaniu.
Losy
J
J
Tokarz-Kupczyk
E
E
Wygladalska-Jernas
H
H
Wender
M
M
D000328:Adult; D015415:Biomarkers; D002908:Chronic Disease; D005260:Female; D005803:Genes, Immunoglobulin / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007145:Immunoglobulin kappa-Chains / Q000276:immunology* / Q000652:urine*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000276:immunology* / Q000652:urine*; D012720:Severity of Illness Index
D015415:Biomarkers; D007074:Immunoglobulin G; D007145:Immunoglobulin kappa-Chains